Recruiting

Non-invasive ICP Monitoring

Sponsor:

HeadSense Medical

Code:

NCT02284217

Conditions

Presence of High Intracranial Pressure

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

EVD

Study Details

Brief summary:

Invasive intracranial pressure (ICP) monitoring is highly effective, but involves risks. HS-1000 measures ICP non-invasively by assessing the acoustic properties of the patient's head. HS-1000 device, a proprietary new non-invasive ICP monitor, is expected to safely and accurately monitor ICP with minimal discomfort to patients, and provide information about normal or elevated ICP levels to the physicians.

The study objective is to compare the accuracy and safety profile of HS-1000, a non-invasive ICP monitor, to invasive ICP monitoring via an external ventricular drain (EVD)

Conditions

Presence of High Intracranial Pressure

Study ID

NCT02284217

Start date

Dec, 2014

Status verified date

Apr, 2016

Completion date

Jan, 2017

Anticipated

Primary completion date

Oct, 2016

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Adult men and women subjects, aged 18 years old and over at screening visit
  • Patients undergoing invasive ICP monitoring via an external ventricular drainage (EVD) device for clinical management
  • Survival expectancy greater than one week
  • Subject or legal authorized representative (per local regulation) is able and willing to comply with the requirements of the protocol
  • Subject or legal authorized representative (per local regulation) is able to understand and sign written informed consent to participate in the study

Exclusion Criteria:

  • Subject with ear disease, ear trauma
  • Subjects with a bony abnormality (skull defect)
  • Subjects with severe head trauma in which the location and/or severity of the skull fracture(s), i.e. frank skull fracture or major joint dislocations may jeopardize HeadSense monitoring procedure
  • Subjects with cerebral fluid (CSF) leakage from the ear (CSF Otorrhea)
  • Known allergy or hypersensitivity to any of the test materials or contraindication to test materials
  • For women of childbearing potential: pregnancy (positive pregnancy test) or breast-feeding
  • Subjects currently enrolled in or less than 30 days post-participation in other investigational device or drug study(s), or receiving other investigational agent(s)
  • Any condition that may jeopardize study participation (e.g., abnormal clinical or laboratory finding) or interpretation of study results, or may impede the ability to obtain informed consent (e.g., mental condition)

Study Design

Enrollment

100 participants

Anticipated

Intervention Model

Single group

Primary purpose

Screening

Interventions and Outcome Measures

Arms

experimental: Patients with invasive ICP monitor (EVD)

Hospitalized patients who have already been implanted with an invasive ICP monitor. Eligible patients will be enrolled into the study and HS-1000 headset portion of the device will be placed in their ears.

Interventions

EVD

ICP monitoring will be done in parallel for both HS-1000 and ICP monitoring via an EVD device (per clinical protocol without any change in the patient's management). HS-1000 ICP monitoring intervals will last from 30 minutes to 6 hours, continuously depending on the patient's clinical condition. Each such interval may occur three times a day or more depending on the clinical condition of the patient.

Primary outcome measure

  • Post-hoc algorithm processing to compare ICP values (mmHg) of the HS-1000 device and invasive ICP monitor collected in each ICP monitoring cycle [ Time Frame: 2 months after last patient \ last visit ]
  • Incidence of AEs through 48 hours from end of ICP monitoring with HS-1000 device [ Time Frame: 48 hours from end of ICP monitoring ]
  • Rate of ear infections/irritations coded and graded using the adapted CTCAE dictionary provided to the site Principal Investigator (PI) [ Time Frame: 48 hours from end of ICP monitoring ]

Central Contacts and Locations

Central contacts

Nichol McBee, MPH, CCRP

(410) 614-6996nmcbee@jhmi.edu

Locations

University of Maryland Medical Center

Recruiting

Baltimore, Maryland, United States, 21201

Contacts

E Francois Aldrich, M.B.,Ch.B.

410-328-0937FAldrich@Smail.umaryland.edu

More Information

Sponsor

HeadSense Medical

Last update posted

Apr 29, 2016

Last verified

Apr, 2016

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by HeadSense Medical on 2016-04-29.